Sitemap
Main menu
- Home
- About The Royal Marsden
- Who we are
- How we run ourselves
- Quality and safety
- Our promise to you
- Confidentiality and medical information
- Infection prevention and control
- Regulatory information
- Annual Report
- Impact Report
- BS EN ISO 9001:2008
- Consultant treatment data
- CQC rating
- Customer Service Excellence
- Integrated governance reports
- JACIE Accreditation
- MHRA Assessment
- NHSLA Level 3
- Patient surveys
- PLACE inspection
- Quality Account and Quality Priorities
- The Information Standard
- The Friends and Family Test
- Reporting Facility time
- Safe staffing levels
- Five-Year Strategic Plan
- Caldicott Guardian
- Nursing Strategy 2016–2018
- Quality Strategy 2015-20
- Sign up to Safety
- Freedom of information
- Our research
- Research strategy
- Our research facilities
- Clinical trials
- What is a clinical trial?
- What types of clinical trial are there?
- How are clinical trials planned?
- How are clinical trials organised?
- How do I decide whether to take part in a clinical trial?
- What does 'giving consent' mean?
- Clinical trials: questions to ask
- Clinical research performance
- Clinical trials: Sources of information and support
- Patient involvement
- Research partners
- Applied health research
- Our research summaries
- Your personal data in research
- Equality and diversity
- Access Policy
- Our consultants, units and wards
- Consultant directory
- Clinical units
- Clinical departments
- The Royal Marsden, Chelsea, London
- Admissions and Pre-assessment Unit, Chelsea
- Burdett Coutts Ward
- Clinical Assessment Unit, Chelsea
- Critical Care Unit
- Day Surgery Unit
- Ellis Ward
- Granard House (private inpatients)
- Granard House (private outpatients)
- Horder Ward
- Markus Ward
- Medical Day Unit, Chelsea
- Outpatients Department, Chelsea
- Private Care Surgical Unit
- Private Patient Medical Day Unit, Chelsea
- Rapid Diagnostic and Assessment Centre, Chelsea
- Surgical Admission Unit
- Wilson Ward
- Wiltshaw Ward (private inpatients)
- The Royal Marsden, Sutton, Surrey
- Admission and Pre-assessment Unit, Sutton
- Bud Flanagan Ambulatory Outpatient Unit
- Bud Flanagan wards and units
- Clinical Assessment Unit, Sutton
- Kennaway Ward
- Medical Day Unit, Sutton
- Minor Procedures Suite
- Mobile Chemotherapy Unit
- Oak Centre for Children and Young People
- Oak Foundation Drug Development Unit
- Outpatients Department, Sutton
- Private Patient Medical Day Unit, Sutton
- Rapid Diagnostic and Assessment Centre, Sutton
- Robert Tiffany Ward (private inpatients)
- Smithers Ward
- Kingston Hospital, Surrey
- Your care
- Diagnosis
- The Royal Marsden Help Centre
- Your visit
- Cancer types
- Blood cancers
- Brain tumour
- Breast cancer
- Cancers of unknown primary (CUP)
- Gastrointestinal
- Gynaecological
- Head and neck
- Lung cancer
- Melanoma
- Paediatric cancers
- Soft-tissue sarcoma
- Ewing’s sarcoma
- Urological cancers (bladder, kidney, prostate, testicular)
- Treatments
- Surgery
- Chemotherapy
- Radiotherapy
- Is radiotherapy an option for me?
- My radiotherapy treatment
- Types of radiotherapy
- Radiotherapy: planning your treatment
- Radiotherapy: preparing for your treatment
- Receiving radiotherapy
- Side effects of radiotherapy
- Radiotherapy: questions you may wish to ask
- Radiotherapy: sources of information and support
- After radiotherapy has finished
- CyberKnife
- Radioisotope therapy
- Supportive therapies
- Outpatient care
- Inpatient care
- Pain management
- Pharmacy
- Support services
- Children and young people
- Patient care
- Physiotherapy (children and young people)
- Occupational therapy (children and young people)
- Speech and language therapy
- Nutrition and dietetics (children and young people)
- Psychological care
- Social, emotional and practical support
- Long-term follow-up
- Symptom management and palliative care
- Safeguarding children
- Speech and language therapy (children and young people)
- Patients aged 1-16 (children)
- Patients aged 16-24 (teenagers and young adults)
- Guides for teachers
- Our partners
- Useful links
- Patient care
- Living with and beyond cancer
- Medicines
- Private Care
- Contact us about private care
- For healthcare professionals
- Getting to The Royal Marsden
- International Patient Centre
- Referring to Private Care
- Why choose The Royal Marsden?
- مركز المرضى الدوليين
- Information for patients
- Request a second opinion
- Уход за онкологическими больными в больнице The Royal Marsden
- Getting involved
- News and events
- Information for GPs
- GP Education Series
- Subscribe to GP Oncology Update
- Webcasts and presentations
- GP Education Series: Head, neck and brain cancers
- GP Education Series: Lung cancer and lymphoma
- GP Education Series: Breast and prostate cancers
- GP Education Series: Upper and lower GI cancers
- GP Education Series: Blood, head and neck cancers
- GP Education Series: Diabetes and cancer
- GP Education Series: Gastrointestinal cancers
- GP Education Series: Urological cancers
- GP Education Series: Urology and children's cancers
- GP Education Series: Women's cancers
- GP Education series: Breast and sarcoma
- Register for a GP Education Day
- GP resources
- Breast cancer
- GP Update
- Surgeons complete UK-first in robotic surgery at The Royal Marsden
- Managing the side effects of immunotherapy treatment
- Targeted treatment and immunotherapy for lung cancer
- Updates to NICE guidance (NG92) on stop smoking interventions
- A new model of palliative care: symptoms trigger service
- Lung cancer update: What you need to know
- Best practice for diagnosing lung cancer
- First patient to be treated on the MR Linac in Autumn 2018
- Watch the video: How to do a breast examination
- Your questions answered on lumps and bumps
- Breast lumps – when to refer
- Head and neck cancer: managing complications of surgery
- Improving cancer outcomes in your practice
- Register for our next GP Education Day
- Breast cancer: Screening
- Case study: Diagnosing gynaecological cancers
- Eating and swallowing after head and neck cancer
- Let's beat oral cancer sooner
- Managing the side effects of breast cancer treatment
- Prostate cancer diagnostic pathway
- Q&A: Blood cancers
- Q&A: Breast cancer
- Q&A: Gynaecological cancers
- Q&A: HPV and cervical cancer
- Q&A: Urological cancers
- T-VEC Immunotherapy treatment for Melanoma
- Watchful waiting and active surveillance
- ‘Game-changing’ drug doubles head and neck cancer survival
- Skin cancer
- GP update
- Referring patients
- GP Education Series